Worldwide Sales of Prescription Generic Drugs to Exceed $48 Billion by 2010

New York, May 5, 2006 — With numerous blockbuster drugs having lost their patents in the last few years, and more than 30 set to experience similar fate during the next four years, sales of prescription generic drugs are expected to soar past 2005 sales of $28.2 billion to reach upwards of $48 billion in 2010.

According to The World Market for Prescription Generic Drugs, a new study released today from Kalorama Information, 2005 revenues grew by 11.2% over 2004’s $25.3 billion, and steady growth is expected to continue at similar growth rates over the next several years. With popular drugs such as Norvasc, Paxil, and Ambien expected to come off patent within the next eight months, anticipation is high within the generic community to capitalize on the phenomenal success of these and other brand name drugs.

Gone are the days of the stigma of generics simply being copycat drugs. A new breed of generic companies is emerging as a far greater threat to brand manufacturers, as the success of generics has spawned explorations into new drug targets, including specialty generics, generics with distinction, generic biologicals, and proprietary molecules.

“The generic landscape is rapidly changing as generic manufacturers are consolidating, using their corporate muscle to influence policy change, and upgrading their drug portfolios,” notes Mary Anne Crandall, the report’s author. “Consumers worldwide, particularly the elderly and those on fixed incomes, are also helping to drive success as their awareness of generics’ cost savings and quality causes them to choose generics over brand name drugs.”

This study examines the global market for generic prescription drugs in all major segments, including: anti-infective, allergy and respiratory, analgesics, NSAIDs and anti-rheumatic, anesthetic, cancer, cardiovascular, CNS, gastrointestinal, hormone, and ophthalmic drugs.

The World Market for Prescription Generic Drugs also includes market analysis and projections for each segment, comparative analysis of U.S. versus world markets, legal and regulatory issues affecting the market, and global market trends affecting growth. It can be purchased directly from Kalorama Information by clicking http://www.kaloramainformation.com/pub/1190851.html. It is also available at MarketResearch.com.

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, a leading provider of industry-specific market research, supplies the latest independent market research on the life sciences. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit www.KaloramaInformation.com.